

MOMENTUM



The international MOMENTUM study brings together partners from academia and industry to track the outcomes of combining Magnetic Resonance and Radiation Therapy to treat common types of cancer using the MR-Linac.

In the MOMENTUM-study, the clinical and technical data of patients treated on the MR-Linac is collected. The data is used for technical development and to facilitate evidence-based implementation of MR-guided radiotherapy.

NEWSLETTER OCTOBER 2021

NEW ON THE MR-LINAC

Patients now have the possibility to watch television during their treatment on the MR-Linac in the UMC Utrecht.

During the period of the Olympic Games all patients requested to watch those competitions.

We are happy we can make treatment time a bit more comfortable on the MR-Linac!



Afbeelding via @radiotherapieumcutrecht / R. Bouwman

MOMENTUM-STUDY REACHES 2000th PATIENT MILESTONE

Just over two and a half years since the study started in 2019, and only nine months after enrolling the 1000th patient, the MOMENTUM study team has now announced that the number of enrolled patients reached 2000 patients last week.

This is great news, as evidence-based introduction of this new technology is facilitated by data gathered from all participants in the study.

The 2000th patient was recruited at the MOMENTUM study partner Odense Universitetshospital (OUH) in Denmark. The MOMENTUM Principal Investigator of the MOMENTUM study at OUH, Dr Tine Schytte, said: "enrolment of patient number 2000 in the MOMENTUM protocol is an important milestone. It reflects the dedication of many individuals and hard work to produce evidence-based implementation of the MR-Linac through international collaboration. We at Odense University Hospital are happy to be part of the project and are looking forward to continuing the collaboration."

Professor Lenny Verkooijen, manager of the MOMENTUM study also welcomed the news: "It is really wonderful to see that 2000 patients have given us permission to use their routine data for research purposes. Thanks to them, we are able to investigate (amongst others) where patients outcomes need to be improved, and in which areas MR-Linac can make most impact in terms of disease control, toxicity reduction, or improved logistics."

PUBLICATIONS

A new edition of the MOMENTUM Newsletter and some attention for these new publications:

Article of Rachel W. Chan et al:

'Chemical exchange saturation transfer MRI in central nervous system tumors on a 1.5 T MR-Linac'


[https://www.thegreenjournal.com/article/S0167-8140\(21\)06647-0/fulltext](https://www.thegreenjournal.com/article/S0167-8140(21)06647-0/fulltext)

Article of Sophie de Mol van Otterloo et al:

'Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry'

<https://www.sciencedirect.com/science/article/abs/pii/S0360301621008725>

RECRUITMENT PER TUMOR SITE | OCTOBER 2021



Date of patient accrual

MOMENTUM SCHOOL

*The start of something new!
We'd like to introduce you to MOMENTUM SCHOOL*

"Knowledge is of no value unless we put it into practice - Anton Chekhov"
This is exactly what we want to achieve with MOMENTUM SCHOOL, short 30 minutes lectures with information that you can use immediately to improve Data Entry. We will start on the 2nd of November 2021 via the online CRC-meeting, hope to see you there!



RADIOTHERAPIEGROEP JOINS OUR MISSION

On 28th of September the Radiotherapiegroep (the Netherlands), Deventer opened a institutional MOMENTUM registry to make use of the MOMENTUM infrastructure.

During a COVID19-proof online kick-off session the new team was introduced to the study. They have now started including new and retro-spective patient information in the MOMENTUM-study database. Welcome!